Lecigon® (U.S. name not specified)
Advanced Parkinson's Disease
Phase 3Active
Key Facts
About Intrance Medical Systems
Intrance Medical Systems is a clinical-stage biotech company targeting a significant unmet need in advanced Parkinson's disease (APD) with its lead product, a continuous intestinal infusion therapy. The product, known as Lecigon® in Europe, combines a proprietary drug gel with a lightweight pump, aiming to provide more stable symptom control than oral medications. Founded in 2015 and based in San Diego, the company is leveraging European regulatory approval and real-world experience to advance its U.S. clinical program, supported by a $17 million Series A financing and a leadership team with deep experience in Parkinson's disease and drug-device combinations.
View full company profileTherapeutic Areas
Other Advanced Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Lecigon | Lobsor Pharmaceuticals | Phase 3 |
| Infudopa IntraV | Dizlin Pharmaceuticals | Pre-clinical |
| SER-252 (POZ-apomorphine) | Serina Therapeutics | Phase 1b |